Back to top
more

Keryx Biopharmaceuticals, Inc. (KERX)

(Delayed Data from NSDQ)

$3.36 USD

3.36
NA

0.00 (0.00%)

Updated Dec 12, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Keryx Biopharma (KERX) Up 4% Since Last Earnings Report?

by Zacks Equity Research

Keryx Biopharma (KERX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Keryx (KERX) Looks Good: Stock Adds 7.2% in Session

by Zacks Equity Research

Keryx (KERX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag

by Zacks Equity Research

Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.

Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

by Zacks Equity Research

Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.

    Keryx (KERX) Loss Wider Than Expected in Q2, Sales Miss

    by Zacks Equity Research

    Keryx Biopharmaceuticals (KERX) reports wider-than-expected loss in Q2, revenues too miss estimates.

      What's in Store for ImmunoGen (IMGN) This Earnings Season?

      by Zacks Equity Research

      ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, is expected to drive investor interest in the second-quarter earnings call.

        Is a Beat in Store for Keryx (KERX) This Earnings Season?

        by Zacks Equity Research

        Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.

          5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates

          by Zacks Equity Research

          Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.

            Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

            by Zacks Equity Research

            Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

              Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall

              by Zacks Equity Research

              Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.

                Why is Keryx (KERX) Down 2.7% Since its Last Earnings Report?

                by Zacks Equity Research

                Keryx (KERX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat

                  by Zacks Equity Research

                  Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.

                    Madhu Goel headshot

                    Keryx (KERX) Posts Narrower Than Expected Q4 Loss, Sales Beat

                    by Madhu Goel

                    Keryx's first-quarter 2018 loss was narrower-than-expected and sales beat estimates.

                      What's in Store for Endocyte (ECYT) This Earnings Season?

                      by Zacks Equity Research

                      Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.

                        5 Biotech Stocks Set to Beat Estimates This Earnings Season

                        by Zacks Equity Research

                        Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.

                          BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?

                          by Zacks Equity Research

                          Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

                            Is a Beat in Store for Epizyme (EPZM) This Earnings Season?

                            by Zacks Equity Research

                            Epizyme (EPZM) is expected to provide updates on pipeline candidates when it reports Q1 results on May 8.

                              Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?

                              by Zacks Equity Research

                              On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.

                                What's in the Offing for Keryx (KERX) This Earnings Season?

                                by Zacks Equity Research

                                Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.

                                  Options Traders Expect Huge Moves in Keryx (KERX) Stock

                                  by Zacks Equity Research

                                  Investors in Keryx (KERX) need to pay close attention to the stock based on moves in the options market lately.

                                    Is the Options Market Predicting a Spike in Keryx (KERX) Stock?

                                    by Zacks Equity Research

                                    Investors need to pay close attention to Keryx (KERX) stock based on the movements in the options market lately.

                                      Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

                                      by Zacks Equity Research

                                      Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.

                                        Keryx (KERX) Posts Wider Q4 Loss, Sales Beat, Shares Down

                                        by Zacks Equity Research

                                        Keryx posted wider than expected loss but beat revenues in the fourth quarter of 2017.

                                          Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?

                                          by Zacks Equity Research

                                          Keryx (KERX) will provide updates on lead drug Auryxia when it reports Q4 results on Feb 7.

                                            Implied Volatility Surging for Keryx Biopharmaceuticals (KERX) Stock Options

                                            by Zacks Equity Research

                                            Investors in Keryx Biopharmaceuticals (KERX) need to pay close attention to the stock based on moves in the options market lately.